Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-00993-8
Abstract: We thank Aksan and colleagues for their interest in our recent article on the budgetary implications of using iron isomaltoside 1000 (IIM) relative to other intravenous (IV) iron formulations in patients with inflammatory bowel disease… read more here.
Keywords: bowel disease; patients inflammatory; inflammatory bowel; isomaltoside 1000 ... See more keywords
NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
Sign Up to like & getrecommendations! Published in 2020 at "BMC Nephrology"
DOI: 10.1186/s12882-020-02180-2
Abstract: Background Intravenous iron is often used to treat iron deficiency anaemia in non-dialysis chronic kidney disease (ND-CKD), but the optimal dosing regimen remains unclear. We evaluated the impact of high- versus low-dose intravenous iron isomaltoside… read more here.
Keywords: study; iron deficiency; iron; 1000 iron ... See more keywords
Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0270640
Abstract: Background Patients with colorectal cancer have a high risk of iron deficiency anaemia (IDA) due to chronic tumour induced blood loss, a reduced dietary iron intake from poor nutrition or gastrointestinal malabsorption. This pilot, double… read more here.
Keywords: iron deficiency; iron; trial; iron isomaltoside ... See more keywords
Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14071408
Abstract: Anemia is a major complication of end-stage kidney disease (ESKD). Erythropoiesis-stimulating agents and intravenous (IV) iron are the current backbone of anemia treatment in ESKD. Iron overload induced by IV iron is a potential clinical… read more here.
Keywords: carboxymaltose iron; iron; ferric carboxymaltose; iron sucrose ... See more keywords